Adherence and Growth Outcomes in a Large Cohort of Children Treated With Recombinant GH Using a Connected Auto-injector
Children using Easypod exhibit high adherence, which aids clinical decision-making and patient engagement. Adherence and catch-up growth decrease with age. Indication for GH treatment had little impact, but overall catch-up growth was significantly greater with high adherence.
Authors
- Quentin Le Masne (ORCID: https://orcid.org/0000-0001-7120-130X)
- Sarah E. Berger (ORCID: https://orcid.org/0000-0003-2794-5517)
- M. Tauber (ORCID: https://orcid.org/0000-0002-0363-7862)
- Agnès Linglart (ORCID: https://orcid.org/0000-0003-3455-002X)
- Paula van Dommelen (ORCID: https://orcid.org/0000-0001-5546-6244)
- Michel Polak (ORCID: https://orcid.org/0000-0003-2639-352X)
- Viviane Jeanbat
- Claire Castello-Bridoux
- Lilian Arnaud (ORCID: https://orcid.org/0000-0003-3028-0253)
- Ekaterina Koledova (ORCID: https://orcid.org/0000-0003-2572-9052)
- Natacha Bouhours‐Nouet
- Mélissande Simonin
- Raphaël Untereiner
Institutions
- Hôpital Necker-Enfants Malades (FR)
- Netherlands Organisation for Applied Scientific Research (NL)
- Inserm (FR)
- Merck KGaA, Darmstadt (Germany) (DE)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Université Paris Cité (FR)
- Université Paris-Saclay (FR)
- Cemka-Eval (France) (FR)
- Sorbonne Paris Cité (FR)
- Hospices Civils de Lyon (FR)
- Akka Technologies (France) (FR)
- Bicêtre Hospital (FR)
- Institut des Maladies Génétiques Imagine (FR)
- Université d'Angers (FR)
Publication Details
- Journal
- Journal of the Endocrine Society
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1210/jendso/bvaf162
- Primary Topic
- Childhood Cancer Survivors' Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Merck KGaA